About This Event

Ligand (Nasdaq: LGND), a biopharmaceutical royalty aggregator focused on investing in highly differentiated development-stage and commercial products, visits the Nasdaq MarketSite in Times Square to commemorate several recent milestones including the company’s transaction with Channel Therapeutics Corporation to launch ZELSUVMI™, the first and only prescription medication approved by the U.S. Food and Drug Administration for the treatment of Molluscum contagiosum infections at home by patients, parents, and caregivers.

In honor of the occasion, Ligand CEO, Todd Davis, rings the Opening Bell.